<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Bexarotene</title>
    <link rel="shortcut icon" href="images/testlogo.png" type="image/x-icon">
    <link rel="stylesheet" href="css.css">
    <style>
        body {
            background-color: rgba(196, 241, 255, 0.562);
        }
        .container {
            text-align: center;
            margin-left: 100px;
            margin-right:100px;
        }
        p {
            font-size: 22px; /* Adjust the font size as desired */
            font-style: italic;
            text-align: justify;
            text-justify: inter-word;
          }
          table {
         border-spacing: 30px;
          }
    </style>
</head>
<body>
    <center>
        <h1>BEXAROTENE</h1><br>
        <table>
            <tr>
                <td><img src="https://i0.wp.com/www.gnhindia.com/wp-content/uploads/2020/05/setid2d1eb4bd-51f9-4c9b-9fb1-0be5e30a3dc5nameimage-01.jpg?fit=891%2C396&ssl=1" width="300px" height="200px" alt=""></td>
                
            </tr>
        </table>
            <div class="container">
                <p>Bexarotene works by selectively binding to specific retinoid receptors in the body, which can help regulate cell growth and differentiation. In CTCL, bexarotene targets and modifies the abnormal T-cells responsible for the cancer, leading to a reduction in tumor size and symptoms.

                    Bexarotene is available in oral capsule form and is typically taken once daily with food. The dosage and duration of treatment may vary depending on the individual's condition and response to the medication. It is important to follow the instructions provided by the healthcare professional.

                </p>
            </div>
    </center>
    
</body>
</html>